Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives Consensus Recommendation of “Buy” from Analysts

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) has received an average recommendation of “Buy” from the fourteen analysts that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $58.1111.

Several research analysts have recently commented on TERN shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Terns Pharmaceuticals in a report on Monday, December 29th. Wall Street Zen raised shares of Terns Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, February 14th. Mizuho lifted their target price on Terns Pharmaceuticals from $33.00 to $54.00 and gave the company an “outperform” rating in a research note on Tuesday, December 9th. TD Cowen raised Terns Pharmaceuticals to a “strong-buy” rating in a report on Friday, February 20th. Finally, Citigroup reiterated an “outperform” rating on shares of Terns Pharmaceuticals in a research report on Wednesday, November 26th.

Insiders Place Their Bets

In other news, CEO Amy L. Burroughs sold 71,339 shares of the business’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $38.10, for a total transaction of $2,718,015.90. Following the completion of the transaction, the chief executive officer owned 138,976 shares of the company’s stock, valued at approximately $5,294,985.60. The trade was a 33.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Emil Kuriakose sold 1,155 shares of the business’s stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $38.57, for a total transaction of $44,548.35. Following the transaction, the insider directly owned 50,365 shares of the company’s stock, valued at approximately $1,942,578.05. This trade represents a 2.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 155,826 shares of company stock valued at $5,882,597. 1.50% of the stock is owned by company insiders.

Institutional Trading of Terns Pharmaceuticals

Several hedge funds have recently bought and sold shares of TERN. Seven Fleet Capital Management LP acquired a new position in Terns Pharmaceuticals during the 4th quarter valued at about $1,491,000. Invesco Ltd. increased its stake in shares of Terns Pharmaceuticals by 26.9% in the fourth quarter. Invesco Ltd. now owns 606,247 shares of the company’s stock valued at $24,492,000 after purchasing an additional 128,573 shares during the period. Mackenzie Financial Corp bought a new stake in shares of Terns Pharmaceuticals during the fourth quarter valued at approximately $215,000. NewEdge Advisors LLC raised its holdings in shares of Terns Pharmaceuticals by 240.0% during the fourth quarter. NewEdge Advisors LLC now owns 9,173 shares of the company’s stock valued at $371,000 after buying an additional 6,475 shares during the last quarter. Finally, ADAR1 Capital Management LLC boosted its position in shares of Terns Pharmaceuticals by 5,316.2% during the fourth quarter. ADAR1 Capital Management LLC now owns 541,615 shares of the company’s stock worth $21,881,000 after buying an additional 531,615 shares during the period. 98.26% of the stock is currently owned by institutional investors.

Terns Pharmaceuticals Price Performance

TERN stock opened at $46.52 on Monday. The firm has a market cap of $4.83 billion, a price-to-earnings ratio of -45.17 and a beta of -0.31. Terns Pharmaceuticals has a 1-year low of $1.87 and a 1-year high of $48.26. The firm has a fifty day moving average price of $38.76 and a two-hundred day moving average price of $26.38.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.